BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ingrezza (Valbenazine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ingrezza (Valbenazine)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05207085-9342@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Ingrezza (Valbenazine): Phase 2 readout est. (NCT05207085)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 2.\nStudy: Efficacy of Valbenazi
 ne for the Treatment of Trichotillomania in Adults\nEstimated primary comp
 letion: 15 February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/valbenazine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05207085
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111988-9342@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ingrezza (Valbenazine): Phase 2 readout est. (NCT07111988)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 2.\nStudy: Valbenazine in Obsess
 ive Compulsive Disorder\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/valbenazine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07111988
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312189-9342@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ingrezza (Valbenazine): Phase 3 readout est. (NCT06312189)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 3\, Huntington's Disease.\nStudy
 : Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Pa
 rticipants With Chorea Associated With Huntington Disease in Canada\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06312189
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105111-9342@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ingrezza (Valbenazine): Phase 4 readout est. (NCT07105111)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 4\, Tardive Dyskinesia.\nStudy: 
 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants
  With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or Af
 ter Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07105111
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
